RELAY THERAPEUTICS INC (RLAY) Stock Income Statement
USA - NASDAQ:RLAY - US75943R1023 - Common Stock
4.005 USD
-0.12 (-2.79%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.36M | 10.01M | 25.55M | 1.38M | 3.03M | |||
| Operating Expenses | 351.42M | 382.48M | 398.55M | 300.66M | 355.87M | |||
| Research and Development | 291.81M | 319.09M | 330.02M | 246.36M | 292.53M | |||
| Selling, General, and Administrative Expenses | 69.02M | 76.59M | 74.95M | 65.98M | 57.39M | |||
| Operating Income | -343.06M | -372.47M | -373.00M | -299.28M | -352.84M | |||
| Interest Income/Expense | 32.17M | 34.75M | 31.05M | 8.79M | -11.03M | |||
| Other Income/Expense | -651.00K | 14.00K | -18.00K | -20.00K | 0.00 | |||
| Non Recurring Items | N/A | N/A | 0.00 | N/A | N/A | |||
| Income Before Taxes | -311.55M | -337.71M | -341.97M | -290.51M | -363.87M | |||
| Net Income | -311.55M | -337.71M | -341.97M | -290.51M | -363.87M | |||
| EBITDA | -338.15M | -367.00M | -367.73M | -295.15M | -348.91M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.95 | -2.36 | -2.79 | -2.59 | -3.82 | |||
| Non GAAP EPS | -1.95 | -2.39 | -2.80 | -2.60 | -3.85 | |||
| Statistics | ||||||||
| Profit Margin | -3728.45% | -3374.72% | -1338.66% | -21051.45% | -12008.91% | |||
| Operating Profit Margin | -4105.60% | -3722.07% | -1460.11% | -21686.96% | -11644.88% | |||
All data in USD